Guidant boosts its pacemaker business in +ACQ-850 million deal
This article was originally published in Clinica
Guidant will acquire Sulzer Medica's +ACQ-323 million electrophysiology business for up to +ACQ-850 million. The deal will give the company a hefty boost to its pacemaker sector, in turn doubling its US sales force and giving it more clout in bundling opportunities to hospitals.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.